⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of Blood Immune Cells in Cancer Patients Compared to Controls

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Blood Immune Cells in Cancer Patients Compared to Controls

Official Title: Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls

Study ID: NCT01312701

Conditions

Solid Carcinoma

Interventions

Study Description

Brief Summary: Tumors have a systemic immune modifying effect. They affect the immune system similarly to states of chronic inflammation and these effects can: * be monitored through analysis of nk t and myeloid cells mainly through studies of the zeta chain but also through other means * may be decreased following effective anticancer therapy - may even be used to study the effectiveness of anticancer therapy * are important to monitor if the investigators plan on formulation of systemic immune therapy Thus immumonitoring of systemic blood cells may turn out to be an important prognostic and predictive factor in many cancer types

Detailed Description: CD247 Known also as the zeta chain is important for relaying T-cell induced signal transduction. Interestingly studies by Baniash and others have demonstrated that this chain is down regulated in states of chronic inflammation and cancer in peripheral blood T cells and also in NK cells However there has not been a prospective study of this marker in cancer and control patients such a study will reveal not only the levels of CD247 in immune cells of cancer patients compared to controls but may reveal the effect of anticancer therapies on CD247 in cancer patients such a study may contribute significantly to our ability to monitor systemic immune system characteristics in cancer patients and help in any further studies of immunomodulation such as vaccination schemes in such patients

Eligibility

Minimum Age: 16 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: Yes

Locations

Oncology day care Oncology Dept Sharett Inst Hadassah Ein Kerem, Jerusalem, , Israel

Contact Details

Name: Hovav Nechushtan, MD PhD

Affiliation: Oncology Dept Hadassah Hebrew University Medical Center

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: